Disialoganglioside GD2 is a promising target for immunotherapy with expression primarily
restricted to neuroectodermal and epithelial tumor cells. Although its role in the maintenance …

Introduction: Ganglioside GD2 is found in vertebrates and invertebrates, overexpressed
among pediatric and adult solid tumors, including neuroblastoma, glioma, retinoblastoma …

Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in
normal tissues, making most subtypes unsuitable as targets for cancer therapy. However …

Part of the broader glycosphingolipid family, gangliosides are composed of a ceramide
bound to a sialic acid-containing glycan chain, and locate at the plasma membrane …

Target selection is a key feature in cancer immunotherapy, a promising field in cancer
research. In this respect, gangliosides, a broad family of structurally related glycolipids, were …

Purpose Disialoganglioside GD 2 is expressed by glioblastoma multiforme (GBM) cells
representing a promising target for anti-GD2 immunotherapeutic approaches. The aim of the …

Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human
cancers and stem cells. They include pediatric embryonal tumors (neuroblastoma …

Disialoganglioside GD2 is an important target on several pediatric and adult cancer types
including neuroblastoma, retinoblastoma, melanoma, small-cell lung cancer, brain tumors …

Disialoganglioside GD2 is highly expressed on neuroectodermal tumors and sarcomas, but
only weakly expressed on limited normal tissues. It has been identified as a marker for a …

In the development of novel immune therapies for high-risk cancers, one goal is to find tumor
targets that are not widely shared by normal cells. One such target is the surface …